Literature DB >> 24092474

Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.

Gjin Ndrepepa1, Franz-Josef Neumann, Salvatore Cassese, Massimiliano Fusaro, Ilka Ott, Stefanie Schulz, Petra Hoppmann, Gert Richardt, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati.   

Abstract

BACKGROUND: Limited information exists on the prognostic impact of bleeding after percutaneous coronary intervention (PCI) in patients with chronic kidney disease (CKD). We investigated the impact of bleeding after PCI on the outcome of these patients.
METHODS: The study included 2,934 patients with estimated creatinine clearance <60 ml/min. Bleeding events within 30 days after PCI were assessed using the Bleeding Academic Research Consortium (BARC) criteria. The primary outcome was 1-year mortality.
RESULTS: Bleeding events occurred in 485 patients (16.5 %). BARC classes were: class 1 (n = 155), class 2 (n = 73), class 3a (n = 182), class 3b (n = 68), class 3c (n = 6) and class 4 (n = 1). There were 212 deaths over the first year after PCI: 60 deaths in patients who bled and 152 deaths in patients who did not bleed (Kaplan-Meier [KM] estimates, 12.5 and 6.3 %; odds ratio [OR] = 2.11, 95 % confidence interval [CI] 1.57-2.83, P < 0.001). Nonfatal myocardial infarction occurred in 71 patients who bled and in 141 patients who did not bleed (KM estimates, 14.8 and 5.8 %; OR = 2.70 [2.05-3.55], P < 0.001). After adjustment, bleeding was independently associated with increased risk of 1-year mortality (adjusted hazard ratio [HR] = 1.90 [1.33-2.72], P < 0.001) and myocardial infarction (adjusted HR = 2.74 [1.99-3.78], P < 0.001). Bleeding improved the discriminatory power of the multivariable model for prediction of mortality (absolute and relative integrated discrimination improvement [IDI], 0.011 and 15.4 %; P = 0.004) or myocardial infarction (absolute and relative IDI, 0.017 and 70.8 %; P < 0.001).
CONCLUSIONS: Peri-PCI bleeding in patients with CKD is independently associated with the increased risk of 1-year mortality and nonfatal myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24092474     DOI: 10.1007/s00392-013-0622-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  33 in total

1.  Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention.

Authors:  N Attallah; L Yassine; K Fisher; J Yee
Journal:  Clin Nephrol       Date:  2005-12       Impact factor: 0.975

Review 2.  Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.

Authors:  Brendan J Doyle; Charanjit S Rihal; Dennis A Gastineau; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

3.  Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.

Authors:  Tobias Pinkau; Gjin Ndrepepa; Adnan Kastrati; Johannes F E Mann; Stefanie Schulz; Julinda Mehilli; Albert Schömig
Journal:  Cardiology       Date:  2008-04-23       Impact factor: 1.869

4.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

5.  Retroperitoneal hemorrhage after percutaneous coronary intervention in the current practice era: clinical outcomes and prognostic value of abdominal/pelvic computed tomography.

Authors:  Gabriel Maluenda; Lavinia Mitulescu; Itsik Ben-Dor; Michael A Gaglia; Gaby Weissman; Rebecca Torguson; Lowell F Satler; Augusto D Pichard; Nelson L Bernardo; Ron Waksman
Journal:  Catheter Cardiovasc Interv       Date:  2011-11-02       Impact factor: 2.692

6.  Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention.

Authors:  Gjin Ndrepepa; Franz-Josef Neumann; Gert Richardt; Stefanie Schulz; Ralph Tölg; Kiril M Stoyanov; Michael Gick; Tareq Ibrahim; Katrin Anette Fiedler; Peter B Berger; Karl-Ludwig Laugwitz; Adnan Kastrati
Journal:  Circ Cardiovasc Interv       Date:  2013-07-23       Impact factor: 6.546

7.  Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?

Authors:  M H Rubenstein; L C Harrell; B V Sheynberg; H Schunkert; H Bazari; I F Palacios
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

8.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

Review 9.  Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options.

Authors:  Olivier Morel; Clotilde Muller; Laurence Jesel; Bruno Moulin; Thierry Hannedouche
Journal:  Nephrol Dial Transplant       Date:  2013-03-08       Impact factor: 5.992

Review 10.  Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs.

Authors:  Steven R Steinhubl; Adnan Kastrati; Peter B Berger
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

View more
  5 in total

1.  Prolonged dual antiplatelet therapy in renal failure: a challenging trade-off.

Authors:  Matthias Bossard; Raban Jeger
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Comparison of modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas in predicting long-term outcomes in patients undergoing stent implantation due to stable coronary artery disease.

Authors:  Tadeusz Osadnik; Jarosław Wasilewski; Andrzej Lekston; Joanna Strzelczyk; Anna Kurek; Aleksander Rafał Gutowski; Krzysztof Dyrbuś; Kamil Bujak; Rafał Reguła; Piotr Rozentryt; Bożena Szyguła-Jurkiewicz; Lech Poloński
Journal:  Clin Res Cardiol       Date:  2014-03-09       Impact factor: 5.460

Review 3.  Revascularization Strategies in Patients with Chronic Kidney Disease and Acute Coronary Syndromes.

Authors:  Evan C Klein; Ridhima Kapoor; David Lewandowski; Peter J Mason
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

4.  Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis.

Authors:  Vojko Kanic; Meta Penko; Franjo Husam Naji; Robert Ekart; Zlatka Kanic; Dejan Dinevski; Radovan Hojs
Journal:  Wien Klin Wochenschr       Date:  2015-09-16       Impact factor: 1.704

5.  Large-scale experience with an anchorless vascular closure device in a real-life clinical setting.

Authors:  Verena Schelp; Sandra Freitag-Wolf; Dieter Hinzmann; Peter Bramlage; Norbert Frey; Derk Frank
Journal:  Clin Res Cardiol       Date:  2014-10-08       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.